Filter your search
Biotechnology markets include the tools, consumables, services and intellectual property necessary for life sciences and applied medical research. The products of such research include biopharmaceuticals, vaccines, and other biologics. Emerging markets like that of mass spectrometry used in clinical testing applications highlight technological advances that urge more companies to make deals in the field of biotechnology. As the industry grows, companies will develop and integrate automated platforms and diagnostic kits that greatly increase convenience and reliability. This efficiency-mindedness had permeated the past decade in the biotechnology field, as the pace and breadth of translational or biomedical research has created multi-billion dollar markets for research tools and services as well as for the discovered and subsequently marketed biologics. In the future, companies hope to see convenient clinical diagnostic applications eventually coming into multiple areas of the clinical lab.
Next Generation Sequencing
Proteomics
Biopharmaceuticals
Instrumentation & Equipment
Emerging Technologies
- $4,200.00 – $8,400.00Proteomics Markets for Clinical IVD Applications and Research Applications Kalorama Information report Proteomics Markets for Research and IVD Applications contains market estimates, forecasts and competitive analysis of this important area. Proteomics is the science of proteins, including the study of the function and form proteins. This includes the study of how and why proteins are […]September 4, 2014$995.00 – $1,990.00miRNA Research and Diagnostics Markets This report, miRNA Research and Diagnostic Markets, focuses on the test product potential of microRNA. These pieces of RNA are seen as important regulators of gene expression; including growth, form, differentiation, and apoptosis. They serve myriad functions as regulator molecules in post-transcriptional gene silencing. As the study details, a wide […]September 4, 2014$995.00 – $1,990.00Recent Biotech Funding, Deals and Partnerships Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete […]May 20, 2014$1,995.00 – $3,990.00For capacity, accuracy, and specificity of analysis, the use of mass spectrometry in clinical diagnostics and clinical research has grown dramatically in recent years. This Kalorama Information report, Mass Spectrometry for Clinical Applications: Market Analysis and End User Survey, looks at the growth of Mass Spec systems being used in diagnostics and other clinical applications […]April 29, 2014$995.00 – $1,990.00Next-Generation Sequencing in Latin America This report is an examination of the use of DNA sequencing systems in the Latin American region, based on a survey conducted in Fall 2013 by VA Consultadoros. The survey centered on instrumentation, with a goal of providing a complete count of next-generation sequencing (NGS) systems sold to customers in […]January 23, 2014$3,995.00 – $7,990.00The effectiveness of biomarkers has made them essential to medicine, with successful products on the market and many products in development. This Kalorama Information report focuses on both the clinical biomarkers and research biomarkers in medicine. Biomarkers are physiologic, genetic or biochemical parameters that provide insight into understanding disease processes and ways that medicines can […]October 16, 2013$3,995.00 – $7,990.00The Market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Circulating tumor cells (CTCs) are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs and forming new tumors. These cells that leave the primary tumor are able to colonize distant organs in the body and initiate […]August 15, 2013$1,500.00 – $3,000.00Next Generation Sequencing Trends (Clinical Applications, Systems Used, Accreditation Status, Regulated Patient Sample Handling and Other Trends) Next-generation sequencing is discussed frequently as a key to clinical diagnostics in the future. This report looks at the status of NGS today, and seeks to provide insights on the “on-the-ground” status of clinical sequencing. In the course […]July 1, 2013$995.00 – $2,000.00Computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. IT companies in collaboration with test vendors are developing computer software that complements the skills of human test interpretation. This report, Bioinformatics in IVD Testing looks at the various IVD market segments where bionformatics is expected to have […]June 7, 2013$995.00 – $1,990.00Epigenetics (“Epi”; “over “ or “above” genetics) is recognized as those systems that control the expression of DNA-coded genes, but do not reside in the base pair sequences of the DNA. Rather, these control mechanisms are based on factors or molecules that bind to specific regions of the DNA (the genome), affecting gene expression. The […]August 10, 2012